Management of Elevated Liver Enzymes with Heavy Alcohol Use

Critical Initial Recognition

The American Association for the Study of Liver Diseases recommends that for a patient with moderately elevated transaminases and heavy alcohol use, immediately implement alcohol cessation interventions while simultaneously ordering GGT and performing non-invasive fibrosis assessment, as normal bilirubin and alkaline phosphatase do not exclude advanced alcohol-related liver disease 1, 2
The AST/ALT ratio of 1.13 suggests early alcoholic liver injury, though ratios >2 are more specific for alcohol-related disease 3
Normal bilirubin and alkaline phosphatase are falsely reassuring - more than 50% of patients with advanced fibrosis from alcohol have normal or minimally elevated transaminases 2
These enzyme levels (both <300 IU/L) are typical for alcohol-related liver disease, which rarely exceeds 300 IU/L even with significant injury 3

The European Association for the Study of the Liver recommends ordering GGT immediately - it detects 75% of habitual drinkers and is more sensitive than transaminases for chronic alcohol exposure 3, 4
Obtain complete metabolic panel including albumin, bilirubin, INR, and platelet count to assess synthetic liver function 3, 2
Calculate precise alcohol consumption using the formula: (volume in mL × alcohol % × 0.785) ÷ 100 to determine grams of alcohol consumed daily 3
Administer AUDIT questionnaire - scores >19 indicate alcohol dependence requiring referral to addiction services 1, 5

Arrange FibroScan or ARFI elastography urgently - this is the critical test that transaminases cannot provide 1, 5, 2
If FibroScan >16 kPa, refer immediately to hepatology for advanced liver disease management 5
If FibroScan shows F3-F4 fibrosis, initiate cirrhosis surveillance including upper endoscopy for varices and ultrasound ± AFP every 6 months for hepatocellular carcinoma screening 2

Implement motivational interviewing using the "5 As" model (Ask, Advise, Assess, Assist, Arrange) with empathic, non-judgmental communication 2
Present objective feedback linking their specific alcohol consumption to liver enzyme elevation and long-term cirrhosis risk 2
Assess readiness to change and respect patient autonomy in decision-making 2
Consider prescribing naltrexone, acamprosate, or disulfiram for patients with alcohol use disorder, as abstinence is the single most important determinant of long-term outcomes 2

Recheck AST, ALT, GGT, albumin, bilirubin, INR, and platelet count in 2-4 weeks if patient achieves abstinence 2, 3
GGT levels recover slowly over months following abstinence, making it useful for monitoring compliance 3
If FibroScan reveals significant fibrosis (F3-F4), establish hepatology co-management for cirrhosis surveillance protocols 2
Address metabolic syndrome components (obesity, hypertension, dyslipidemia) that commonly coexist and synergize with alcohol to accelerate liver damage 1, 2
Prescribe thiamine 100 mg daily, folate 1 mg daily, and multivitamin to address nutritional deficiencies common in heavy drinkers 2